Pfizer inks collaboration deal to use CytoReason's cell-centered models of immune system

Microsoft has revamped its MMLSpark open source project (Image kamisoka / iStockPhoto)
CytoReason expects to receive payments from Pfizer that could reach into “low double-digit millions” of U.S. dollars. (kamisoka/iStockPhoto)

Pharma giant Pfizer has inked a deal with CytoReason to use the Tel Aviv-based drug discovery and development company’s cell-centered models of the immune system.

CytoReason’s machine learning technology can rebuild lost cellular information from gene expression data and associate genes to specific cells. In turn, that information is integrated with other data to create a cell-based model of the trial-specific immune response.

Although financial terms of the deal weren’t disclosed, CytoReason expects to receive payments from Pfizer that could reach into “low double-digit millions” of U.S. dollars.

Webinar

Lipid-based Formulations for Early Stage Clinical Trials

Liquid-filled capsule technology has a proven record for addressing complex API formulation challenges, but also offers a simple and effective pathway to the clinic. Register now to learn more about lipid-based formulations.

“This will be our fifth major partnership, which we believe will help make our model unparalleled in its accuracy for assets across the pipeline,” David Harel, CytoReason’s chief executive, said in a statement (PDF). “CytoReason’s model brings together thousands of samples on a cell-protein-gene level, allowing for fast and accurate insights.”

So far, the company has two pending patents, 10 commercial and scientific collaborations and 16 peer-reviewed publications. Its technology can target cancer immunotherapy, autoimmune, neurodegenerative and infectious diseases.

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.